NovaMedica is a modern Russian pharmaceutical company established in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica strategy is aimed at attraction into Russia of intellectual property rights for innovative pharmaceutical products and technologies as well as at development and implementation of own R&D-projects and creation of a modern pharmaceutical GMP manufacturing facility.

NovaMedica owns intellectual property rights within Russia and the CIS for 36 innovations which are part of the portfolio of RusnanoMedInvest, venture capital foundation. NovaMedica pipeline includes antivirus and anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases.

In April 2017, NovaMedica launched NovaMedica Innotech (R&D Center), which gives pharmacists and researchers the latest technological opportunities that were previously unavailable in the Russian pharmaceutical industry. The opening ceremony was attended by Moscow Mayor Sergei Sobyanin, Deputy Minister of Industry and Trade Oleg Bocharov, Chairman of the Management Board of RUSNANO Anatoly Chubais and leaders of the Russian and Western pharmaceutical industry.

At the end of 2017, NovaMedica Innotech R&D Center received a manufacturing license and a GMP certificate from the Ministry of Industry and Trade of the Russian Federation, which gives it the opportunity to manufacture drug products, conduct research activities in the framework of developing innovative drug products, and engage in contract manufacturing.

NovaMedica is already working under development of a number of its own drug products. The plans include development of 15 drug products until 2022. 11 of them are already at different stages - from creation of a dosage form to clinical studies and state registration, and 4 more - at the launch stage. These drugs are for the treatment of diseases in the field of gastroenterology, neurology, ophthalmology and rheumatology, as well as for pain relief.

In 2016 NovaMedica became the key partner in Russia of one of the world pharmaceutical leaders – Pfizer. The goal of the partnership is to create in our country a modern pharmaceutical facility for manufacturing of sterile injectable forms, and where a large portfolio of drugs from Pfizer portfolio will be localized.

In May 2017, the construction of this facility started in the Kaluga region, Technopark Vorsino. Anatoly Chubais, Chairman of the Management Board of RUSNANO, Anatoly Chubais, Deputy Minister of Industry and Trade, Anatoly Artamonov, the head of the region, and the leaders of our team were launching this large and important construction project.

In 2017, for this agreement on long-term cooperation and the project NovaMedica and Pfizer received industry recognition - they won the open professional competition "Platinum Ounce" in the nomination "Deal of the Year".

In March 2018, NovaMedica signed SPIC with the Ministry of Industry and Trade of the Russian Federation and the Kaluga Region, the main goal of which is to invest over 3 billion rubles in the construction of modern pharmaceutical manufacturing facility. The SPIC was signed by the head of the Ministry of Industry and Trade of the Russian Federation Denis Manturov, the Governor of the Kaluga region Anatoly Artamonov and the General Director of NovaMedica Alexander Kuzin in the presence of the Vice-Premier Arkady Dvorkovich and the head of the MC "Rusnano" Anatoly Chubais.

Also NovaMedica has a developed, efficient infrastructure for the promotion and sale of pharmaceutical products. Here NovaMedica has such partners as Pfizer, SIFI, Ferring, MIR-PHARM, Obninsk Chemical and Pharmaceutical Company, etc.

NovaMedica team consists of top managers with many years of successful implementation of projects in the field of pharmaceuticals. The leaders of the team repeatedly entered the list of business leaders of the TOP-1000 managers of Russia (2017, 2016), according to the Association of Managers of Russia and the Kommersant Publishing House.

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more